The clinical-stage biopharmaceutical company named Julie Eastland as chief executive officer, president and director. She succeeds Kimberly Blackwell, who will remain as a strategic advisor to the ...

Palantir stock has gained 248% year-to-date, driven by expanding profit margins and strong revenue growth. In Q3 of 2024, its ...